ACURX PHARMACEUTICALS INC (ACXP)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.42+1.43%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ACXP
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance dropped from the top half to the bottom half of its industry over the past month — the reason to own it has weakened.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
ACXP — private placement
Dated 2026-04-16
Entry into a Material Definitive Agreement. On April 15, 2026, Acurx Pharmaceuticals, Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the investors named therein (the “Investors”), pursuant to which the Company agreed to issue and sell, in a registered direct offering by the Company directly to the Investors (the “Registered Offering”) (i) 816,068 shares (the “Shares”) of common stock, par value $0.001 per share, of th…
Why it matters: Plans for a Phase 3 trial show progress in the ibezapolstat program.
Supportive ifThe company announces a timeline for starting the Phase 3 trial after the pilot trial.
Worry ifNo updates or delays in announcing the Phase 3 trial plans after the pilot trial.
Why it matters: Good results may lead to FDA approval. This could mean big market potential for Acurx.
Supportive ifThe pilot trial shows good results for the 20 patients who took part.
Worry ifThe trial shows bad results or big delays in progress.
Why it matters: If used, this could give Acurx more money for its projects.
Supportive ifAcurx says many short-term warrants are being used.
Worry ifFew or no short-term warrants are exercised within the 24-month period.
Why it matters: Progress in the rCDI program is key for Acurx's future. It could change treatment standards.
Supportive ifAcurx shares good results from the pilot trial for ibezapolstat.
Worry ifThe trial results are disappointing or delayed, impacting the Phase 3 trial timeline.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$214 on $10,000 · ±2.1% | How much price usually moves either way. |
| Bad day | $987 loss on $10,000 · 9.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,333 loss on $10,000 · 83.3% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: This program is important for Acurx's growth in antibiotics.
Supportive ifThe company announces the start of the Phase 3 trial for ibezapolstat in rCDI.
Worry ifNo updates on the trial or delays in starting the Phase 3 trial.
Why it matters: Positive results could support the move to a Phase 3 trial for rCDI. This is key for future growth.
Supportive ifThe trial shows good results in patients with recurrent CDI.
Worry ifThe trial does not show good results or is delayed.
Why it matters: This offering is important. It will help fund Acurx's antibiotic programs and operations.
Supportive ifThe offering will close on or around April 16, 2026. Acurx will receive all funds.
Worry ifThe offering fails to close or raises less than $2.5 million.
Why it matters: Using warrants could give Acurx more money. This money helps develop antibiotics.
Supportive ifAt least 50% of the short-term warrants are exercised within the 24-month period.
Worry ifLess than 10% of the short-term warrants are exercised by the expiration date.
Why it matters: Aligning pay can help management do better and build investor trust.
Supportive ifLook for a new pay plan that matches company performance.
Worry ifLeaders' pay continues to mismatch with company goals.
Why it matters: If this capital raise works, it could boost investor confidence and stock liquidity.
Watch forShare price stays the same or goes up after the private placement is done.
Also watch forShare price drops a lot after the private placement announcement.